We are live on ! Find out more
SAM

Sectoral Asset Management Portfolio holdings

AUM $121M
1-Year Est. Return 73.47%
This Fund
S&P 500
This Quarter Est. Return
+11.33%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$914M
AUM Growth
+$58.1M
Cap. Flow
-$16.6M
Cap. Flow %
-1.81%
Top 10 Hldgs %
41.85%
Holding
74
New
9
Increased
27
Reduced
22
Closed
13

Top Buys

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$33.6M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$25M
3
LJPC
La Jolla Pharmaceutical Company
LJPC
+$14.7M
4
XLRN
Acceleron Pharma
XLRN
+$13.9M
5
EVH icon
Evolent Health
EVH
+$12.8M

Top Sells

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$30.3M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$29.7M
3
TDOC icon
Teladoc Health
TDOC
+$15M
4
ALDR
Alder Biopharmaceuticals
ALDR
+$14.8M
5
ISRG icon
Intuitive Surgical
ISRG
+$10.6M

Sector Composition

Rank Sector Weight
1 Healthcare 94.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARAV
51
DELISTED
Aravive, Inc. Common Stock
ARAV
$1.83M 0.2%
+17,460
New +$1.88M
OBSV
52
DELISTED
ObsEva SA Ordinary Shares
OBSV
$1.82M 0.2%
212,831
+137,331
+182% +$1.02M
IMDZ
53
DELISTED
Immune Design Corp.
IMDZ
$1.64M 0.18%
+168,300
New +$1.18M
FSTX
54
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$1.52M 0.17%
+28,125
New +$1.3M
PTCT icon
55
PTC Therapeutics
PTCT
$6.52B
$1.11M 0.12%
60,735
-290,400
-83% -$3.91M
SAGE
56
DELISTED
Sage Therapeutics
SAGE
$972K 0.11%
12,199
– –
SRPT icon
57
Sarepta Therapeutics
SRPT
$1.82B
$971K 0.11%
28,799
– –
TGTX icon
58
TG Therapeutics
TGTX
$8.4B
$817K 0.09%
81,266
-56,234
-41% -$629K
TRIL
59
DELISTED
Trillium Therapeutics Inc.
TRIL
$806K 0.09%
183,272
+55,000
+43% +$304K
RDY icon
60
Dr. Reddy's Laboratories
RDY
$10.5B
$803K 0.09%
95,325
-65,450
-41% -$532K
SRRA
61
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$236K 0.03%
5,042
– –
ALNY icon
62
Alnylam Pharmaceuticals
ALNY
$35.7B
– –
-24,899
Closed -$1.28M
BIIB icon
63
Biogen
BIIB
$30.4B
– –
-11,711
Closed -$3.2M
CLDX icon
64
Celldex Therapeutics
CLDX
$2.77B
– –
-16,879
Closed -$914K
CRVS icon
65
Corvus Pharmaceuticals
CRVS
$1.25B
– –
-67,200
Closed -$1.4M
MOH icon
66
Molina Healthcare
MOH
$11.7B
– –
-81,575
Closed -$3.72M
NVO
67
Novo Nordisk
NVO
$223B
– –
-434,960
Closed -$7.46M
XENT
68
DELISTED
Intersect ENT, Inc
XENT
– –
-143,240
Closed -$2.46M
ADXS
69
DELISTED
Advaxis Inc
ADXS
– –
-55,985
Closed -$6.86M
ALDR
70
DELISTED
Alder Biopharmaceuticals
ALDR
– –
-713,119
Closed -$14.8M
AVXS
71
DELISTED
AveXis, Inc. Common Stock
AVXS
– –
-14,950
Closed -$1.14M
KITE
72
DELISTED
Kite Pharma, Inc.
KITE
– –
-63,520
Closed -$4.99M
SHPG
73
DELISTED
Shire pic
SHPG
– –
-173,679
Closed -$30.3M
1 2
3

Similar funds

RIP
Reliant Investment Partners Pinehurst, North Carolina $121M AUM 34.77% 1-Year Est. Return
CCM
Chicago Capital Management Chicago, Illinois $121M AUM 74.36% 1-Year Est. Return
LFWA
LiftPoint Family Wealth Advisors Far Hills, New Jersey $121M AUM
FWA
Fulcrum Wealth Advisors Bellevue, Washington $121M AUM
CF
Conquis Financial Milbrae, California $121M AUM 16.22% 1-Year Est. Return
WIM
Wiregrass Investment Management Thomasville, Georgia $121M AUM
MW
Merited Wealth North Bay Village, Florida $121M AUM
AFC
Avise Financial Cooperative Los Angeles, California $121M AUM

Sectoral Asset Management's Q2 2017 Portfolio in Review

As of Q2 2017, Sectoral Asset Management held 74 positions worth $914M, up 6.8% from $856M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Sectoral Asset Management's Q2 2017 filing shows 9 new, 27 increased, 22 reduced and 13 closed positions. Its largest new stake was Medtronic: 398,360 shares worth $35.4M. The largest sale was Shire pic, an estimated $30.3M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 94% a quarter earlier.

  • Sectoral Asset Management's largest Q2 2017 buy was Medtronic: 398,360 shares worth $35.4M.
  • Sectoral Asset Management added most to Regeneron Pharmaceuticals in Q2 2017, an estimated $25M increase.
  • Sectoral Asset Management's biggest Q2 2017 reduction was Neurocrine Biosciences, cutting an estimated $29.7M.
  • Sectoral Asset Management fully exited Shire pic in Q2 2017, selling an estimated $30.3M.
  • Sectoral Asset Management's ten largest holdings make up 42% of its $914M portfolio in Q2 2017.
  • Sectoral Asset Management opened 9 new positions and closed 13 in Q2 2017.
  • Sectoral Asset Management's portfolio value rose 6.8% quarter-over-quarter to $914M.

Based on Sectoral Asset Management's 13F filing for Q2 2017, filed 14 Aug 2017.